{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:23:37Z","timestamp":1772756617109,"version":"3.50.1"},"publisher-location":"Chichester, UK","reference-count":56,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002832","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:38:44Z","timestamp":1069385924000},"source":"Crossref","is-referenced-by-count":2,"title":["Perazine for schizophrenia"],"prefix":"10.1002","author":[{"given":"S","family":"Leucht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,21]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD002832-BIB1|cit1","first-page":"151","article-title":"Antipsychotic efficacy of trimipramine: double-blind comparison with a classical neuroleptic","volume":"30","author":"Bender","year":"1997","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1002\/14651858.CD002832-BIB2|cit2","first-page":"780","article-title":"Schizoaffective disorders - testing of antipsychotic components of trimipramine","volume":"10","author":"Blaeser-Kiel","year":"1996","journal-title":"TW Neurologie Psychiatrie"},{"key":"10.1002\/14651858.CD002832-BIB3|cit3","first-page":"60","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Ackenheil","year":"1988"},{"key":"10.1002\/14651858.CD002832-BIB4|cit4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-1000730","article-title":"Efficacy andtolerance of zotepine in a double-blind comparison with perazine in schizophrenics","volume":"59 Suppl. 1","author":"Dieterle","year":"1991","journal-title":"Fortschritte der Neurologie und Psychiatrie"},{"key":"10.1002\/14651858.CD002832-BIB5|cit5","first-page":"340","article-title":"Comparison of zotepine and perazine in schizophrenia","volume":"96 Suppl. 1","author":"Dieterle","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD002832-BIB6|cit6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-2007-1000732","article-title":"Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double-blind controlled study","volume":"59","author":"M\u00fcller-Spahn","year":"1991","journal-title":"Fortschritte der Neurologie und Psychiatrie"},{"key":"10.1002\/14651858.CD002832-BIB7|cit7","first-page":"85","article-title":"Clinical relevance of the test dose model for drug choice and response in acute schizophrenia","volume":"25","author":"Klimke","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB8|cit8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-2007-1014337","article-title":"Initial improvement as a criterion for drug choice in acute schizophrenia","volume":"26","author":"Klimke","year":"1993","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB9|cit9","first-page":"65","volume-title":"Therapie mit Neuroleptika - Perazin","author":"R\u00fcther","year":"1988"},{"key":"10.1002\/14651858.CD002832-BIB10|cit10","series-title":"Proceedings of the 14. CINP-Congress, Florence","article-title":"Relationship between neuroleptic medication, handwritng area and therapeutic repsonse","author":"K\u00fcstner","year":"1984"},{"key":"10.1002\/14651858.CD002832-BIB11|cit11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-2007-1017282","article-title":"Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?","volume":"19","author":"Meya","year":"1986","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB12|cit12","first-page":"55","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Renfordt","year":"1988"},{"issue":"9","key":"10.1002\/14651858.CD002832-BIB13|cit13","first-page":"530","article-title":"A double-blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients","volume":"53","author":"Schmidt","year":"1982","journal-title":"Nervenarzt"},{"issue":"8","key":"10.1002\/14651858.CD002832-BIB14|cit14","first-page":"910","article-title":"A double-blind comparison of the antipsychotic efficacy of perazine compared to haloperidol","volume":"32","author":"Schmidt","year":"1982","journal-title":"Arzneimittel-Forschung"},{"key":"10.1002\/14651858.CD002832-BIB15|cit15","first-page":"40","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Sch\u00fcssler","year":"1988"},{"key":"10.1002\/14651858.CD002832-BIB16|cit16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-1000731","article-title":"Zotepine versus perazine in paranoid schizophrenia: a double-blind controlled trial of antipsychotic efficacy","volume":"59 Suppl.1","author":"Wetzel","year":"1991","journal-title":"Fortschritte der Neurologie und Psychiatrie"},{"key":"10.1002\/14651858.CD002832-BIB17|cit17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0924-977X(99)80361-7","article-title":"Evaluation of dry mouth and its treatment in the course of antipsychotic pharmacotherapy","volume":"9, Suppl. 5","author":"Bender","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD002832-BIB18|cit18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0924-977X(99)80359-9","article-title":"Effect of olanzapine on salivation is less prominent than predicted by its in vitro muscarinic binding profile","volume":"9, Suppl. 5","author":"Czekalla","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD002832-BIB19|cit19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0006-2952(92)90015-B","article-title":"Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes","volume":"44","author":"Fischer","year":"1992","journal-title":"Biochemical Pharmacology"},{"key":"10.1002\/14651858.CD002832-BIB20|cit20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2007-1019594","article-title":"Predictors of the course of schizophrenic diseases under neuroleptic long-term medication","volume":"14","author":"Gaebel","year":"1981","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB21|cit21","article-title":"Low-dose neuroleptic treatment in neurotic disorders","author":"Gaebel","year":"1986","journal-title":"Poster presented at the 15. CINP-Congress; San Juan, Puerto Rico"},{"key":"10.1002\/14651858.CD002832-BIB22|cit22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-2007-1017019","article-title":"Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine","volume":"21","author":"Gaebel","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB23|cit23","article-title":"Early pharmacokinetic and clinical data as predictors of response to acute antipsychotic treatment with perazine","author":"Gaebel","year":"1986","journal-title":"Poster presented at the 15. CINP-Congress; San Juan, Puerto Rico"},{"key":"10.1002\/14651858.CD002832-BIB24|cit24","first-page":"43","article-title":"Early treatment effects of perazine as predictor of acute antipsychotic treatment outcome in schizophrenics","volume":"59, Suppl. 5","author":"Gaebel","year":"1986","journal-title":"Acta Pharmacolgica Toxicologica"},{"key":"10.1002\/14651858.CD002832-BIB25|cit25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02190342","article-title":"Facial expression and emotional face recognition in schizophrenia and depression","volume":"242","author":"Gaebel","year":"1992","journal-title":"Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD002832-BIB26|cit26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000026619","article-title":"The influence of clozapine and typical neuroleptics on information processing of the central nervous sstem under cinical conditions in schizophrenic disorders: implications for fitness to drive","volume":"40","author":"Grabe","year":"1999","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD002832-BIB27|cit27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0924-977X(99)80290-9","article-title":"Quality of life of schizophrenic patients treated with classic and \"old\" atypical neuroleptics","volume":"9, Suppl. 5","author":"Jarema","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD002832-BIB28|cit28","series-title":"Proceedings of the 20th Symposium of the AGNP, N\u00fcrnberg","article-title":"Paroxetine augmentation of neuroleptic treatment in chronic schizophrenia: An open pilot study","author":"Jockers-Scher\u00fcbl","year":"1997"},{"key":"10.1002\/14651858.CD002832-BIB29|cit29","first-page":"51","volume-title":"Therapie mit Neuroleptika-Perazin","author":"Kuhs","year":"1988"},{"key":"10.1002\/14651858.CD002832-BIB30|cit30","first-page":"315","article-title":"Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug","volume":"229","author":"Pietzcker","year":"1981","journal-title":"Archives of Psychiatry and Neurological Sciences"},{"key":"10.1002\/14651858.CD002832-BIB31|cit31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-2007-1017430","article-title":"The outpatient clinic for patients under chronic lithium treatment as a phase-IV research tool","volume":"17","author":"Pietzcker","year":"1984","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB32|cit32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2007-1019489","article-title":"Prediction and evaluation criteria in perazine therapy of acute schizophrenics: Methodological considerations, sample population, and research variables","volume":"16","author":"Rein","year":"1983","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB33|cit33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-2007-1019490","article-title":"Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results","volume":"16","author":"Schied","year":"1983","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB34|cit34","first-page":"721","article-title":"Assessment of neuroleptic therapy in schizophrenic patients admitted to a university psychiatric department","volume":"59","author":"Schmidt","year":"1988","journal-title":"Nervenarzt"},{"issue":"1","key":"10.1002\/14651858.CD002832-BIB35|cit35","first-page":"24","article-title":"Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia","volume":"23","author":"Terminska","year":"1989","journal-title":"Psychatria Polska"},{"issue":"2-3","key":"10.1002\/14651858.CD002832-BIB36|cit36","first-page":"94","article-title":"Orthostatic challenge during neuroleptic test dose: A possible predictor of short-term outcome","volume":"30","author":"Volz","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002832-BIB37|cit37","first-page":"256","volume":"67","author":"Wetterling","year":"1996","journal-title":"Nervenarzt"},{"issue":"2","key":"10.1002\/14651858.CD002832-BIB38|cit38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF02244218","article-title":"Savoxepine: Invalidation of an \"atypical\" neuroleptic response pattern predicted by animal models in an open clinical trial with acute schizophrenic patients","volume":"103","author":"Wetzel","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD002832-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002832-BIB40|cit40","volume-title":"Das AMDP-System: Manual zur Dokumentation psychiatrischer Befunde","author":"AMDP","year":"1981"},{"issue":"8","key":"10.1002\/14651858.CD002832-BIB41|cit41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT Statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002832-BIB42|cit42","volume-title":"Psychiatrische Pharmakotherapie","author":"Benkert","year":"1996"},{"key":"10.1002\/14651858.CD002832-BIB43|cit43","volume-title":"Internationale Skalen f\u00fcr Psychiatrie","author":"CIPS","year":"1986"},{"key":"10.1002\/14651858.CD002832-BIB44|cit44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002832-BIB45|cit45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD002832-BIB46|cit46","first-page":"534","volume":"197","author":"Enss","year":"1958","journal-title":"Archiv f\u00fcr Neurologie und Nervenkrankheiten"},{"key":"10.1002\/14651858.CD002832-BIB47|cit47","first-page":"201","article-title":"Classification of abnormal involuntary movements in psychiatric patients","volume":"2","author":"Gerlach","journal-title":"Neuropsychiatric Clinics"},{"key":"10.1002\/14651858.CD002832-BIB48|cit48","first-page":"74","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Grohmann","year":"1988"},{"key":"10.1002\/14651858.CD002832-BIB49|cit49","series-title":"Proceedings of the II International Conference of the Manfred Sakel Foundation","article-title":"Long-term pharmacotherapy of schizophrenia","author":"Hippius","year":"1962"},{"key":"10.1002\/14651858.CD002832-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002832-BIB51|cit51","volume-title":"Die Eigenschaftsw\u00f6rterliste (EWL-K). Ein Verfahren zur Messung der Befindlichkeit","author":"Janke","year":"1977"},{"key":"10.1002\/14651858.CD002832-BIB52|cit52","first-page":"463","volume":"9","author":"Kr\u00fcger","year":"1963","journal-title":"Medizinische Welt"},{"key":"10.1002\/14651858.CD002832-BIB53|cit53","first-page":"9","volume-title":"Therapie mit Neuroleptika - Perazin","author":"Menge","year":"1988"},{"key":"10.1002\/14651858.CD002832-BIB54|cit54","unstructured":"Mulrow CD Oxman AD Cochrane Collaboration Handbook [updated 1 March 1997] The Cochrane Collaboration The Cochrane Library [database on disk and CD-ROM] Oxford Update Software; 1996-. Updated quarterly"},{"key":"10.1002\/14651858.CD002832-BIB55|cit55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD002832-BIB56|cit56","first-page":"3","article-title":"Brain dopamine receptors","volume":"32","author":"Seeman","year":"1981","journal-title":"Pharmacological Review"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:13:03Z","timestamp":1628543583000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002832"}},"subtitle":[],"editor":[{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2002,1,21]]},"references-count":56,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002832","relation":{},"subject":[],"published":{"date-parts":[[2002,1,21]]}}}